‘Thanks to President Biden, the US now supports a suspension of intellectual property (IP) rights to increase vaccine supplies. However, without vaccine developers sharing tacit technical knowledge for safe vaccine mass production, it will be difficult to rapidly scale up vaccine output.’
This story is well argued and contains several relevant and informative links under the following subheadings:
- Waiver delayed is waiver denied
- Foot dragging for profit
- Vaccine monopolies not yet IP dependent
- Vaccine profits kill
- TRIPS discourages knowledge sharing
- Accelerate vaccinations for all
Read here (IPS News, May 11, 2021)
